Efficacy and safety of cladribine in patients with multiple sclerosis depending on age Review article
Article Sidebar
Main Article Content
Abstract
The distinction between multiple sclerosis forms based on the age of onset is supported primarily by differences in clinical presentation. This division is also reflected in the process of changes occurring in the immune system over time. The aging process affects all organs and increases the risk of other diseases, including infections, cancer and cardiovascular diseases. Data regarding cladribine treatment indicate a maintained safety profile obtained in clinical trials in specific age groups. Due to the awareness of the increased risk of these diseases associated with age, multiple sclerosis and immunomodulatory treatment, active risk management through vaccinations and preventive examinations is important.
Article Details
Copyright © by Medical Education. All rights reserved.
References
1. Adamczyk-Sowa M, Nowak-Kiczmer M, Jaroszewicz J et al. Immunosenescence and multiple sclerosis. Neurol Neurochir Pol. 2022; 56(3): 220-7.
2. Graves JS, Krysko KM, Hua LH et al. Ageing and multiple sclerosis. Lancet Neurol. 2023; 22(1): 66-77. http://doi.org/10.1016/S1474-4422(22)00184-3.
3. Ministerstwo Zdrowia. Zintegrowana Platforma Analityczna. Stwardnienie Rozsiane.
4. Cook S, Leist T, Comi G et al. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult Scler Relat Disord. 2019; 29: 157-67.
5. Leist T, Cook S, Comi G et al. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020; 46: 102572.
6. Chalendar D, Gutirrez A. Early Clinical Experience With Cladribine Tablets in a Real-World Aging Population. Int J MS Care. 2022; 24(suppl 1).
7. Disanto G, Moccia M, Sacco R et al. Monitoring of safety and effectiveness of cladribine in multiple sclerosis patients over 50 years. Mult Scler Relat Disord. 2022; 58: 103490.
8. Giovannoni G, Coyle PK, Vermersch P et al. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. Front Immunol. 2021; 12: 763433.
9. Otero-Romero S, Lebrun-Frénay C, Reyes S et al. ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs. Mult Scler. 2023; 29(8): 904-25.
10. Lycett MJ, Lea RA, Maltby VE et al. The effect of cladribine on immunoglobulin levels compared to B cell targeting therapies in multiple sclerosis. Mult Scler J Exp Transl Clin. 2023; 9(1): 20552173221149688.
11. Buscarinu MC, Reniè R, Morena E et al. Late-Onset MS: Disease Course and Safety-Efficacy of DMTS. Front Neurol. 2022; 13: 829331.
12. Żur-Wyrozumska K. Stwardnienie rozsiane o późnym początku. Dobór terapii w kontekście starzenia się układu immunologicznego. Pol Przegl Neurol. 2023; 19(2): 123-38.